Pilot Study Award Program

The Pilot Study Award Program provides modest research support for new and innovative research projects relevant to Clinical and Translational Science (CTS). Pilot projects must be focused on translational science, i.e., focused on understanding a scientific or operational principle underlying a step of the translational process with the goal of developing generalizable principles to accelerate translational research. Translational research projects that are focused on crossing a particular step of the translational process for a particular target or disease are not allowed.

Projects are intended to: (1) explore possible innovative new leads or new directions for established investigators; (2) stimulate investigators from other areas to lend their expertise in research in CTS; and (3) provide initial support to establish proof of concept. Projects must be feasible within the proposed timeframe, have high methodological and scientific quality, and answer important scientific questions. Pilot project support is not intended for large projects by established investigators that would otherwise be submitted as separate research grant applications.

The program is a component of the UM1 TR004407-04 Clinical Translational Science Awards from the National Institutes of Health (NIH). Four grants will be awarded with budgets limited to $50,000 in direct costs (excluding consortium F&A). Final funding decisions will be made based on award of UM1 grant to SRTI. Research proposed in the application must be completed with all funds spent by April 30, 2027. All projects must align with current NIH priorities.

The relevance to Clinical and Translational Science (CTS) section should explain how the proposed study has the potential to elucidate a scientific or operational principle underlying a step of the translational process with the goal of developing generalizable principles to accelerate translational research. Translational research projects that are focused on crossing a particular step of the translational process for a particular target or disease are not allowed. 

‘Translation’ is defined by NCATS as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and communities—from diagnostics, preventions and treatments to medical procedures and behavioral changes. 

‘Translational research’ (TR) is defined by NCATS as the endeavor to traverse a particular step of the translational process for a particular target or disease. 

‘Translational science’ (TS) is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process. 

Whereas translational research focuses on the specific case of a target or disease, translational science is focused on the general case that applies to any target or disease; advances in translational science are the focus of this FOA. A key tenet of translational science is to understand common causes of inefficiency and failure in translational research projects (e.g., incorrect predictions of the toxicity or efficacy of new drugs, lack of data interoperability or ineffective clinical trial recruitment). Many of these causes are the same across targets, diseases and therapeutic areas; therefore, advances in translational science will increase the efficiency and effectiveness of translational research to enhance health, lengthen life and reduce the burdens of illness and disability. Like any other science, translational science seeks to elucidate general operative principles to transform translation from an empirical, phenomenological process into a predictive science. The application of scientific and operational innovation and strategies to improve the efficiency and effectiveness of all research is at the heart of developing, demonstrating and disseminating the science of translation. 

An example—for illustration only—may help clarify the distinction between TR and TS. An investigator who wishes to test whether a particular drug improves outcomes in diabetes will need to recruit sufficient desired participants; this is a TR problem and will be addressed from the standpoint of effectiveness for the drug’s effects and the diabetes community, using established recruitment methods. By contrast, an investigator who wishes to understand the fundamental underlying mechanisms to recruitment for clinical trials generally, and test an intervention directed at those hypothesized causes and mechanisms, is engaging in TS. To test the hypothesis, the TS investigator may choose a use case that may in fact be the same as that used by the TR researcher—in this example, a drug for diabetes—but the question to be answered is primarily whether the TS innovation accomplishes full recruitment of the desired population more effectively and efficiently. 

Postdoctoral fellows/associates, staff scientists and faculty at Scripps Research are able to apply and serve as PI. Please refer to Policy 401: Eligibility to Serve as PI. Scripps Health physicians and San Diego State University research scientists and faculty may serve as co-investigators via a sub-award. However, a Scripps Research PI must serve as the prime awardee. 

Applicants should design studies that meet the following criteria: 

• Advance Clinical and Translational Science (CTS)
• Integrate Community Engagement principles into study design
• Agnostic and multi-disciplinary; connect basic and clinical science
• Potential to impact clinical practice in a relatively short span of time
• Sound hypothesis, research methodology and statistical considerations
• Track record of the applicant and the co-investigator(s)
• Likelihood of leading to future independent funding and publication

Recipients of the Pilot Study Awards must adhere to all federal, state and local guidelines with respect to scientific conduct, conflict-of-interest policies, participation of human subjects, the use of animals, hazardous or radioactive materials and recombinant DNA in their research studies. 

There will be a two-stage review process. First, all applications will be screened by the Management Committee to ensure that the pilot projects advance CTS principles. Next, the selected applications (finalists) will pass into the second stage peer review process. In this stage, the finalists will receive 2-3 written critiques followed by an NIH-style study section review and ranking by the Scientific Review Committee (composed of 15-20 scientists and physicians). Please note: Only the applications that are selected for the second stage peer review (finalists) will undergo PreAward review at OSP. 

Applications will be scored on a 1-to-5 scale where “1” is excellent and “5” is poor. Half points may be given (e.g., 2.5). Applications that receive an overall average score of 1.5 are generally funded. 

PLEASE NOTE THAT THE APPLICATION DEADLINE FOR 2026 HAS PASSED.

• Letter of Intent (LOI) Deadline—January 16, 2026
• Application Deadline—February 13, 2026
• Initial Screening (Stage 1)—February 25, 2026
• Reviewer Critique Deadline—April 10, 2026
• Study Section (Stage 2)—April 22, 2026
• Earliest Funding Start Date—May 1, 2026

Please send your application to Michelle Miller ([email protected]) by February 13, 2026. 

The LOI is a short summary of the proposal (one page maximum) that must include the following: 

• Title
• Project site(s)
• Names/affiliations of collaborators
• Specify whether Human Subjects or Vertebrate Animals will be used

All applicants that submit an LOI will be invited to submit a full application. The LOI is solely used to determine administrative workload. Please send LOI to Michelle Miller ([email protected]) by January 16, 2026. 

Please complete all fields as accurately as possible, including Project Title, Diseases Targeted, Principal Investigator (PI), Co-Investigator (Co-I) if applicable, eRA Commons ID(s), Institution, Translational or Clinical Liaison (if applicable), as well as contact information. The cover page needs to be signed and dated. 

eRA Commons ID 

List the eRA Commons ID for all investigators listed on the cover page. If you do not have a registered eRA Commons ID, please submit a request to the Office of Sponsored Programs and Compliance (OSPC) via the intranet: https://scrippsresearch.sharepoint.com/sites/ospc/SitePages/eRA-Commons.aspx. 

For additional assistance, contact the NIH eRA Commons Help Desk at [email protected]. 

Type of Investigator—Clinical or Translational 

Check the box for “Clinical” and/or “Translational” to categorize the PI and Co-I’s expertise. If neither is appropriate, check “N/A” and then designate a translational and/or clinical research liaison. A liaison would be someone who is simply advising or mentoring the basic scientist or clinician researcher (PI or Co-I) on the proposed project, but is not integrally involved in the project. A liaison is not required in the presence of a clinical/translational investigator. If there is no clinical/translational investigator, a liaison is required.

Please note: If a liaison is selected, you must include a letter of support from this individual. 

Type of Research 

Human Subjects Research 

If the proposed project involves Human Subjects, indicate whether the IRB protocol is Approved or Pending in the checkbox. If the proposed project does not involve Human Subjects, please indicate Not Applicable in the checkbox. If the proposed project does involve Human Subjects, a copy of the IRB approval letter must be submitted to NCATS at a later date. Please note NCATS requires the title on institutional IRB approval letter to match the title of the proposed pilot project. 

If the project is awarded, then a complete NCATS Human Subjects Prior Approval application is REQUIRED within 30 days of funding notice. The time commitment for preparing the NCATS Human Subject Prior Approval application is substantial. If your study receives a fundable score and it involves Human Subjects, you are required to submit a complete NCATS Human Subject Prior Approval application to Emily Todd ([email protected]). A Notice of Award will not be issued until approval is received from NCATS. Please see “Prior Approval” section for specific requirements. 

Animal Subjects Research 

If the project involves Animal Subjects Research, indicate whether the IACUC protocol is Approved or Pending in the checkbox. An IACUC review is required and a copy of the IACUC approval letter is required as part of the application. If the project is awarded, then a complete NCATS Live Vertebrate Animals Prior Approval application is REQUIRED within 30 days before the proposed implementation of research. A Prior Approval Request application includes: the NCATS Prior Approval Checklist, vertebrate animals study justification and IACUC approval letter. Please note NCATS requires the title on institutional IACUC approval letter to match the title of the proposed pilot project. 

If your study receives a fundable score and it involves vertebrate animals, you are required to submit a complete NCATS Vertebrate Animal Prior Approval application to Emily Todd ([email protected]). A Notice of Award will not be issued until approval is received from NCATS. Please see “Prior Approval” section for specific requirements. 

Stem Cell Research 

If the project involves Stem Cell Research, check whether the ESCRO protocol is approved or pending. If the project does not involve Stem Cell Research, please check Not Applicable. 

If the project involves Stem Cell Research, submit a copy of the ESCRO, or full approval face page, as part of the application. IRB review may be required in addition to ESCRO review. Please note that NCATS requires title on institutional IRB letter to match the title of proposed pilot project. If the project is awarded funding, then a copy of the approved protocol page(s) will be REQUIRED within 30 days of funding notice. 

Abstract/Project Summary 

The abstract should provide a brief and concise summary of the proposed study (approximately 500 words). 

Translational Relevance to Disease/Health 

The relevance to disease/health section should explain how the proposed study has the potential to impact clinical practice in a relatively short period of time (approximately 200 words). 

Relevance to Clinical and Translational Science (CTS) 

The relevance to Clinical and Translational Science (CTS) section should explain how the proposed study has the potential to elucidate a scientific or operational principle underlying a step of the translational process with the goal of developing generalizable principles to accelerate translational research. Translational research projects focused on crossing a particular step of the translational process for a particular target or disease are not allowed. 

‘Translation’ is defined by NCATS as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and communities—from diagnostics, preventions and treatments to medical procedures and behavioral changes. 

‘Translational research’ (TR) is defined by NCATS as the endeavor to traverse a particular step of the translational process for a particular target or disease. 

‘Translational science’ (TS) is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process. 

Whereas translational research focuses on the specific case of a target or disease, translational science is focused on the general case that applies to any target or disease; advances in translational science are the focus of this FOA. A key tenet of translational science is to understand common causes of inefficiency and failure in translational research projects (e.g., incorrect predictions of the toxicity or efficacy of new drugs, lack of data interoperability or ineffective clinical trial recruitment). Many of these causes are the same across targets, diseases and therapeutic areas; therefore, advances in translational science will increase the efficiency and effectiveness of translational research to enhance health, lengthen life and reduce the burdens of illness and disability. Like any other science, translational science seeks to elucidate general operative principles to transform translation from an empirical, phenomenological process into a predictive science. The application of scientific and operational innovation and strategies to improve the efficiency and effectiveness of all research is at the heart of developing, demonstrating and disseminating the science of translation. 

An example—for illustration only—may help clarify the distinction between TR and TS. An investigator who wishes to test whether a particular drug improves outcomes in diabetes will need to recruit sufficient desired participants; this is a TR problem and will be addressed from the standpoint of effectiveness for the drug’s effects and the diabetes community, using established recruitment methods. By contrast, an investigator who wishes to understand the fundamental underlying mechanisms to recruitment for clinical trials generally, and test an intervention directed at those hypothesized causes and mechanisms, is engaging in TS. To test the hypothesis, the TS investigator may choose a use case that may in fact be the same as that used by the TR researcher—in this example, a drug for diabetes—but the question to be answered is primarily whether the TS innovation accomplishes full recruitment of the desired population more effectively and efficiently. 

For more information about translational science, please use the following link: https://ncats.nih.gov/about/about-translational-science 

Community Engagement 

Community Engaged Research (CEnR) is a collaborative process wherein community members—who are often the targets of research studies—are involved in the development, execution and dissemination of research endeavors that may affect them. The ultimate goal of CEnR is to improve the health of community members while simultaneously advancing research discovery in multiple areas of health and wellness.  

Explain how the proposed project involves input from community members to advance health and wellness (approximately 200 words). Need support? Request it here or email [email protected]. 

The SHARC team is available to provide knowledge, skills and resources in community and collaboration, statistics and how to navigate a research grant. The SHARC team is a collaboration between the Scripps Research Translational Institute and Scripps Health. 

The project/research proposal must include the following sections (three pages maximum): 

• Specific Aims
• Background and Medical Significance
• Preliminary Data (if any)
• Research Design and Methods

 
Additional requirements: 

• Figures are allowed within the proposal, but must remain within the page limit.
• Margins must remain at 0.5 inches on all sides with the Translational Institute logo in the header.

List references for the proposal (maximum of 10 references). 

Research proposed in the application must be accomplished and funds spent by April 30, 2027. 

Budget justification may be itemized by category, but must include the following sections: 

• Personnel (list title, percent effort on project and requested salary including benefits)
• Supplies (itemized)
• Other Expenses
• Indirect Costs at Current Federally Negotiated Rate

Biosketches are required for key personnel in the application. Please use the NIH formatted Biosketch. For instructions on how to prepare a Biosketch, please click here. 

Only those applications selected for the second stage peer review process (finalists) will undergo the PreAward review process at OSP. Finalists must submit their applications to OSP PreAward by March 2, 2026. To initiate the process, create the record in the Streamlyne Proposal Development module (use the Non S2S template): 

Complete all required fields of the PD record and provide as attachments: Animal and Human Subject Compliance (including Human Subjects Education Certification for all Key Personnel involved in Human Subjects Research).

• If applicable, Scripps Research is Prime with a Subaward (required forms are available on the OSP website)

  
Attach the completed SRTI Pilot Award Application:

• Face/Cover/Title Page
• Abstract Page/Performance Site/Key Personnel
• Budget and Budget Justification
• Biographical Sketch (for Key Personnel and Liaisons only)
   

Finalists only

Route your application for review through the Streamlyne system by March 2, 2026. Once review is complete and PI approval has been received, PreAward will email completed final applications to Michelle Miller. 

If the project is awarded, then a complete NCATS Human Subjects Prior Approval application is REQUIRED within 30 days of funding notice. Institutional IRB review is required for every proposal involving Human Subject research. The risk level assigned by the Scripps IRB determines the NCATS Prior Approval package. A Prior Approval application can involve the following: 

NCATS HSRPA Application submission in eRA HSS 

NCATS HSRPA Addendum 

IRB Approval letter or Institutional Exemption Determination (Note: NCATS requires title on institutional IRB letter to match the title of proposed pilot project.) 

Human Subjects Training Certificates for PI and Key Persons 

Inclusion Enrollment Report (including gender, race, ethnicity and age for all subjects) 

Biosketches for PI and Key Persons not contained in the CTSA grant application (greater than minimal risk and NIH-defined clinical trials only) 

IRB-Approved Protocol (greater than minimal risk and NIH-defined clinical trials only) 

IRB-Approved Consent (greater than minimal risk and NIH-defined clinical trials only) 

Registration with ClinicalTrials.gov (NIH-defined clinical trials only) 

A common misunderstanding we see when receiving pilot award applications is incorrectly assigning ‘non-human subjects research’ to studies. A study does not have to prospectively enroll subjects into a clinical trial to be considered human subjects research. Some examples of human subjects research that will likely be exempt research or minimal risk are: a) using previously collected samples to do an assay; b) creating a biorepository; or c) retrospective chart reviews. Please note that all these examples are human subjects research and will require prior approval to NCATS. Some examples of non-human subjects research are: a) research involving all deceased individuals; b) research from commercially available cell lines; or c) interviews or surveys that do not collect identifiable information. Scripps IRB will determine if your project is non-human subjects research, exempt research, minimal risk research or greater than minimal risk research. NIH defined clinical trials, greater than minimal risk studies or studies that include a foreign component do require an extra level of review at NCATS and will require 30 business days for NCATS review.  

Due to the current IRB turnaround times, we suggest submitting your pilot project for institutional IRB review as soon as possible (especially if you are prospectively enrolling into a clinical trial). Therefore, if your project is funded, the 12-month award period is not affected by waiting for IRB review. If your proposed pilot project is already IRB approved under a larger encompassing project, you still must submit for IRB review to match the pilot project title. If you have any questions regarding this requirement or definitions of human subjects research as they apply to your project, please see NCATS guidelines  or mail Emily Todd at [email protected] at any time. 

NCATS Prior Approval for research involving Live Vertebrates is required for any study conducting vertebrate animal research. Requests for Prior Approval must be submitted in writing to NCATS no later than 30 days before the proposed implementation of research. See NCATS guidelines for more details or contact Emily Todd at [email protected]. 

If you receive a fundable score and your study involves human subjects or vertebrate animals, you will need to complete an NCATS Prior Approval. The NCATS Prior Approval packet must be submitted to Emily Todd ([email protected]), which will then be forwarded to NCATS for review. 

Note: Approval can take 30-60 days, so please get started on this early, otherwise the Notice of Award will be delayed. 

• NCATS does not allow mixed funds to be used for their funded grant projects.
• The project must be feasible to complete within the year grant cycle.
• K12 scholars are encouraged to apply for pilot funding, however the proposals must be different and funding not mixed.
• Ensure your proposal fits the definitions of translational science, described in “Relevance to Clinical and Translational Science” under “Program Information” above. Projects centered around a single target are not translational science.

Accelerating drug discovery via agentic annotation of ligandable protein sites
Bruno Melillo, PhD

Translational targeting of the GLP-1 system for alcohol misuse
Marisa Roberto, PhD

Utilizing multiple cohorts to build methods for identifying digital biomarkers and predictors of prognoses
Julia Vogel, PhD

Simulating antigenic drift by incorporating in vitro functional measurements and in silico fitness predictions into phylogenetic models
Karthik Gangavarapu, PhD

Harnessing protective Unfolded Protein Response pathways to treat inflammatory bowel disease 
Enrique Saez, PhD 

Highly multiplexed amplicon-based virus sequencing for low-cost and sensitive infectious disease detection and characterization 
Joshua Levy, PhD 

Circadian modulation of belzutifan efficacy and toxicities in ccRCC Treatment clinical models, renal cells 
Katja Lamia, PhD 

Mapping the Presentable Peptidome: A High-Throughput Approach to Neoantige Discovery 
Joseph Jardine, PhD 

Developing a translational workflow for treatment of persistent infections 
Malina Anna Bakowski, PhD 

Detecting and forecasting the growth of emerging viral lineages using wastewater genomic surveillance 
Karthik Gangavarapu, PhD 

An omnigenic, integrative meta-prediction framework for individualized medicine—application  to glaucoma 
Salvatore Loguercio, PhD 

Establishing real-time population-scale immunosurveillance using wastewater 
Jyothi Purushotham, PhD, and Mark Zeller, PhD 

Drug repurposing for antivirals against monkeypox infections  
Juan C. de la Torre, PhD  

CD14 as a target for acute kidney injury in deceased donor kidneys procured for transplant 
Dianne McKay, MD 

Design new covalent drugs by click chemistry 
Barry Sharpless, PhD, and Xiaohua Wu, PhD 

Development of a blood-based diagnostic test for neurodegeneration 
John R. Yates, III 

Combinatorial single-cell CRISPR screen to analyze tumor-specific activation of a novel oncology prodrug in vivo 
Brunie Felding, PhD 

Deciphering the role of mucosal associated invariant T cells in the mucosa of pediatric ulcerative colitis patients 
Luc Teyton, MD, PhD 

Investigating circadian regulation of HIF2a in patient-derived RCC tissue samples 
Katja Lamia, PhD 

Human innate and innate-like lymphocytes in early life 
Michael Constantinides, PhD 

Ruxolitinib-reshaped immunity to overcome anti-PD1 resistance in Hodgkin lymphoma 
John Teijaro, PhD 

Scripps Electronic Medical Records and Genomics (eMERGE Resource) 
Ali Torkamani, PhD 

Structure-activity relationship studies on novel small molecule IRE1 arm-selective unfolded protein response activators for the treatment of alpha-1 antitrypsin deficiency 
Jeffery Kelly, PhD 

San Diego Epidemiology and Research for COVID-19 Health (SEARCH) 
Kristian Andersen, PhD 

Pharmacological expansion of self-renewing CD8 T cells to enhance checkpoint blockade therapy 
John Teijaro, PhD 

Improving vision and visual function in patients with macular degeneration using allosteric modulators of rhodopsin 
Anne Hanneken, MD 

Functional dissection of the brain-heart-kidney axis underlying cardiovascular homeostasis 
Vineet Augustine, PhD 

Diagnosing infectious disease patients using unbiased pathogen detection 
Kristian Andersen, PhD 

Microbial targets of human-secreted anti-proteolytic proteins during intestinal inflammation 
Dennis Wolan, PhD 

Biomarkers of immune tolerance to peanut allergy 
Mansun Law, PhD 

Assessment of JAML-CAR in melanoma to predict response to immunotherapy 
Wendy Havran, PhD 

Assessing resistance mechanisms to facilitate the development of the arylomycins as antibiotics 
Floyd Romesberg, PhD 

Cellular markers of severe Lassa fever to determine patient outcomes 
Biran Sullivan, PhD 

Development of small molecular kinetic stabilizers of amyloidogenic light chains to ameliorate cardiomyopathy 
Jeffery Kelly, PhD 

Identifying therapeutic targets and mechanisms for the strongest genetic risk factor for coronary artery disease using genome edited iPSCs and single cell profiling 
Kristen Baldwin, PhD 

Faculty Awardees 

Identification of biomarkers to predict severity of Lassa fever  
Brian Sullivan, PhD 

Developing preclinical candidates for GI and pancreatic cancer 
Matthew Disney, PhD 

Discovery of novel small-molecule activators of autophagy for the treatment of Parkinson’s disease 
Jeffery Kelly, PhD 

Pilot study of muscle myosin as prothrombotic factor 
John Griffin, PhD 

Preclinical investigations of ROR1 x CD3 bispecific antibodies in B-cell malignancies 
Christoph Rader, PhD 

Gene Expression Profiling of Delayed Graft Function (DGF) in Peripheral Blood & Kidney Allografts 
Christopher Marsh, MD 

KL2 Scholar Awardees

Digital Health, Biophysical Markers and Patient Reported Outcomes: Gaining Objectivity in Assessing Acute or Chronic Pain in Children with Serious Illnesses  
Toluwalase Ajayi, MD 

The Freshman Sleep and Health (FRoSH) Project 
Stuti Jaiswal, MD, PhD 

Alterations in the human gut microbiome and RNA expression during implementation of an autoimmune paleo diet for inflammatory bowel disease 
Gauree Konijeti, MD 

Precision medicine analysis of eosinophilic esophagitis (EoE): Roles of sex-specific immunoregulation of esophageal inflammation and fibrosis, and evaluation of potential novel therapeutics
Quan Nhu, MD, PhD 

Faculty Awardees 

New Diagnostic Tools for Transthyretin Amyloidoses: Focus on an Early Diagnosis Biomarker 
Jeffery Kelly, PhD 

A Cell-based, Non-infectious Platform For Drug Repurposing Screen To Discover Inhibitors Of Hemorrhagic Fever Arenaviruses 
Juan C. de la Torre, PhD 

Defining the tissue bioavailability of small molecule ER proteotoxic regulators to treat protein misfiling diseases 
Luke Wiseman, PhD  

Development of a single-test unbiased pathogen detection platform
Kristian G. Andersen, PhD 

Colorectal Cancer Hematologic and Neoplasmic Genomics (CHANGE) Trial 
Ali Torkamani, PhD 

Click-Seq: Novel methods for single HIV genome sequencing 
Bruce Torbett, PhD 

KL2 Scholar Awardees

Investigating the possibility of a genetic predisposition to hospital and ICU delirium 
Stuti Jaiswal, MD, PhD 

Discovery of novel markers for early diagnosis of type 1 diabetes using single cell expression 
Brian Abe, MD, PhD 

Assessment of Physician Mental Health Using Voice Analysis, Physiological Metrics and Smartphone Enabled Behavioral Modification 
Paddy Barrett, MD, BCh, BAO, MRCPI, MCTI 

Shotgun Epigenetics: A genome-wide, multi-dimensional strategy to study epigenetic regulation of memory CD4 T cell activation and immune networks in ulcerative colitis 
Gauree Konijeti, MD 

Faculty Awardees 

Mechanisms and consequences of mosaic APP amplification in sporadic AD neurons 
Jerold Chun, MD, PhD 

A cell-based, non-infectious platform for drug repurposing screen to discover inhibitors of hemorrhagic fever arena viruses 
Juan C. de la Torre, PhD 

Establishment of a liver organic-derived culture system for hepatitis B virus antiviral screening 
Urtzi Garagorta, PhD  

Repeat-associated non-ATG translation in Fuchs Endothelial Corneal Dystrophy 
Joel Gottesfeld, PhD 

Epigenetic changes in CpG methylation status in the blood of patients with kidney transplant rejection: Mapping immune networks and predicting risk of rejection 
Dan Salomon, MD 

Click-Seq: Novel methods for single HIV genome sequencing 
Bruce Torbett, PhD 

A digital karyotyping screen of circulating DNA for early cancer detection 
Ali Torkamani, PhD